David A. Siegel Zynerba Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.3 - $0.43 $6,270 - $8,987	-20,900 Reduced 14.42%	124,000 $40,000
Q1 2023 May 15, 2023	SELL	$0.4 - $0.67 $16,440 - $27,537	-41,100 Reduced 22.1%	144,900 $62,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $0.72 $5,800 - $8,352	-11,600 Reduced 5.87%	186,000 $98,000
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $1,305 - $2,040	1,500 Added 0.76%	197,600 $145,000
Q2 2022 Aug 15, 2022	BUY	$0.86 - $2.06 $46,870 - $112,270	54,500 Added 38.49%	196,100 $224,000
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $62,403 - $102,982	34,100 Added 31.72%	141,600 $290,000
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $195,264 - $291,540	-67,800 Reduced 38.68%	107,500 $310,000
Q3 2021 Nov 15, 2021	BUY	$3.72 - $5.35 $173,724 - $249,844	46,700 Added 36.31%	175,300 $743,000
Q2 2021 Aug 16, 2021	SELL	$3.83 - $5.98 $150,519 - $235,014	-39,300 Reduced 23.41%	128,600 $680,000
Q1 2021 May 17, 2021	BUY	$3.33 - $8.76 $559,107 - $1.47 Million	167,900 New	167,900 $781,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.